Maruho
Manufacturing · Japan · 1K - 5K Employees
View Company Info for Free
Overview
Headquarters
2763 Takamiya-cho, Hikone, Shiga Prefect...Phone Number
+81 749235541Website
www.maruho.co.jpRevenue
$769.7 MillionIndustry
About Maruho
Maruho Org Chart
Is Maruho your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Maruho recently announced quarterly report
Check if Maruho has recently received funding, and reach out quickly before it becomes old news!
Maruho, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Maruho launches new products
Funding: Get notified immidiatlly once Maruho has new funding data
Click to see if Maruho had a recent Job posting/layoffs
Check out if Maruho is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Maruho
Recommended Actions
Find VP level buyers at Maruho
Find more new buyers
Company Profile Activity
Activity Insights
Maruho is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Maruho is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Maruho.
Maruho Tech Stack
A closer look at the technologies used by Maruho
Most Recent Scoops
Maruho News & Media
Nielsen Biosciences Announces Enrollment of First Patient in Phase 3 Trial of CANDIN for the Treatment of Common Warts
SAN DIEGO--(BUSINESS WIRE)--Nielsen BioSciences, Inc. (“Nielsen”), a privately-held, San Diego-based biopharmaceutical company, today announced the first patient enrolled in CFW-3A – a Phase 3, randomized, double-blind, placebo-controlled study of the safety and efficacy of CANDIN® for the treatment of Verruca vulgaris (common warts) in adolescents and adults. The study is ongoing and will continue to enroll patients across sites in the U.S. and Japan, making this Nielsen’s first clinical studyAOB Pharma and Maruho enter into an Exclusive License Agreement for AOB Pharma's Topical Biologic B244 for the Treatment of Inflammatory Indications including Atopic Dermatitis in Japan
The license is exclusive for the territory of Japan and contains rights for future indications Maruho is responsible for conducting and bearing costs for development in Japan, which will be conducted jointly with AOB Pharma as part of a Global Phase 3 Study for Atopic Dermatitis...Nielsen BioSciences, Inc. Enters into License Agreement with Maruho Co. Ltd. for the Treatment of Common Warts
SAN DIEGO--(BUSINESS WIRE)--Nielson BioSciences enters into a license agreement with Maruho Co. for the treatment of common warts.Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
WILMINGTON, Del. & OSAKA, Japan--(BUSINESS WIRE)---- $INCY--Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Maruho
Maruho Co., Ltd. has its headquarters in Osaka and leads Japan in research and development, manufacturing and commercialization of dermatological products. Founded in 1915, Maruho has 1,546 employees (as of the end of September 2021), and net sales were approximately 87.03 billion yen in its fiscal year ended September 30, 2021. Pursuing its long-t... Read More